Michael H. Tomasson

17.7k total citations
116 papers, 3.5k citations indexed

About

Michael H. Tomasson is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Michael H. Tomasson has authored 116 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 88 papers in Hematology, 50 papers in Molecular Biology and 45 papers in Oncology. Recurrent topics in Michael H. Tomasson's work include Multiple Myeloma Research and Treatments (66 papers), Protein Degradation and Inhibitors (24 papers) and Acute Myeloid Leukemia Research (14 papers). Michael H. Tomasson is often cited by papers focused on Multiple Myeloma Research and Treatments (66 papers), Protein Degradation and Inhibitors (24 papers) and Acute Myeloid Leukemia Research (14 papers). Michael H. Tomasson collaborates with scholars based in United States, Canada and Spain. Michael H. Tomasson's co-authors include Ravi Vij, Jennifer Cain, D. Gary Gilliland, Julie O’Neal, Martin Carroll, Ifor R. Williams, D. Gary Gilliland, Richard A. Van Etten, George F. Barker and Todd R. Golub and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Investigation and Nature Medicine.

In The Last Decade

Michael H. Tomasson

109 papers receiving 3.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael H. Tomasson United States	32	1.8k	1.6k	1.3k	659	486	116	3.5k
Hendrik De Raeve Belgium	34	1.3k 0.7×	1.4k 0.9×	1.1k 0.9×	391 0.6×	366 0.8×	91	2.9k
David R. Stover United States	23	960 0.5×	1.4k 0.9×	1.1k 0.9×	408 0.6×	401 0.8×	47	3.0k
Lewis C. Strauss United States	27	1.5k 0.8×	955 0.6×	1.2k 0.9×	1.3k 1.9×	803 1.7×	64	3.8k
Mark van Duin Netherlands	24	1.8k 1.0×	1.9k 1.1×	1.4k 1.1×	223 0.3×	445 0.9×	71	3.3k
Stefan Früehauf Germany	31	1.6k 0.9×	1.1k 0.7×	1.0k 0.8×	584 0.9×	553 1.1×	119	3.1k
Shmuel Yaccoby United States	38	3.7k 2.0×	3.0k 1.8×	3.0k 2.4×	522 0.8×	537 1.1×	112	5.5k
Katharina S. Götze Germany	29	2.7k 1.5×	1.7k 1.1×	498 0.4×	1.3k 1.9×	380 0.8×	130	3.9k
Kai Neben Germany	41	2.5k 1.4×	2.3k 1.4×	1.5k 1.2×	739 1.1×	162 0.3×	111	4.2k
Abraham Avigdor Israel	32	1.4k 0.8×	969 0.6×	1.6k 1.3×	559 0.8×	755 1.6×	139	3.7k
Jean‐Michel Cayuela France	33	2.1k 1.2×	1.0k 0.6×	784 0.6×	837 1.3×	552 1.1×	101	3.8k

Countries citing papers authored by Michael H. Tomasson

Since Specialization

Citations

This map shows the geographic impact of Michael H. Tomasson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael H. Tomasson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael H. Tomasson more than expected).

Fields of papers citing papers by Michael H. Tomasson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael H. Tomasson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael H. Tomasson. The network helps show where Michael H. Tomasson may publish in the future.

Co-authorship network of co-authors of Michael H. Tomasson

This figure shows the co-authorship network connecting the top 25 collaborators of Michael H. Tomasson. A scholar is included among the top collaborators of Michael H. Tomasson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael H. Tomasson. Michael H. Tomasson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bahlis, Nizar J., Caitlin Costello, Noopur Raje, et al.. (2023). Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial. Nature Medicine. 29(10). 2570–2576. 76 indexed citations

Niesvizky, Rubén, Bertrand Arnulf, Mohamad Mohty, et al.. (2023). Clinical Factors Associated with Cytokine Release Syndrome and Dosing Recommendations for Restarting Elranatamab Following an Interruption. Blood. 142(Supplement 1). 3384–3384. 2 indexed citations

Mahajan, Nitin, Melissa L. Bates, Chakrapani Tripathi, et al.. (2019). The snoRNA target of t(4;14) in multiple myeloma regulates ribosome biogenesis. FASEB BioAdvances. 1(7). 404–414. 18 indexed citations

Altrock, Philipp M., et al.. (2018). Computational Model of Progression to Multiple Myeloma Identifies Optimum Screening Strategies. JCO Clinical Cancer Informatics. 2(2). 1–12. 8 indexed citations

White, Brian S., Irena Lanc, Julie O’Neal, et al.. (2018). A multiple myeloma-specific capture sequencing platform discovers novel translocations and frequent, risk-associated point mutations in IGLL5. Blood Cancer Journal. 8(3). 35–35. 35 indexed citations

Hao, Mu, Hao Xu, John D. Shaughnessy, et al.. (2017). NEK2 induces osteoclast differentiation and bone destruction via heparanase in multiple myeloma. PMC. 1 indexed citations

Tang, Min, Rui Zhao, Helgi van de Velde, et al.. (2016). Myeloma Cell Dynamics in Response to Treatment Supports a Model of Hierarchical Differentiation and Clonal Evolution. Clinical Cancer Research. 22(16). 4206–4214. 20 indexed citations

Pan, Dipanjan, Grace Cui, Angana Senpan, et al.. (2015). Small Molecule MYC Inhibitor Conjugated to Integrin-Targeted Nanoparticles Extends Survival in a Mouse Model of Disseminated Multiple Myeloma. Molecular Cancer Therapeutics. 14(6). 1286–1294. 45 indexed citations

Pan, Dipanjan, Christine T. N. Pham, Katherine N. Weilbaecher, et al.. (2015). Contact‐facilitated drug delivery with Sn2 lipase labile prodrugs optimize targeted lipid nanoparticle drug delivery. Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology. 8(1). 85–106. 28 indexed citations

10.

Miller, Christopher A., Brian S. White, Nathan D. Dees, et al.. (2014). SciClone: Inferring Clonal Architecture and Tracking the Spatial and Temporal Patterns of Tumor Evolution. PLoS Computational Biology. 10(8). e1003665–e1003665. 281 indexed citations

11.

Fiala, Mark A., Jingxia Liu, Keith Stockerl‐Goldstein, et al.. (2014). The impact of race and socioeconomic status on survival in multiple myeloma.. Journal of Clinical Oncology. 32(15_suppl). e17554–e17554. 1 indexed citations

12.

Wildes, Tanya M., Mark A. Fiala, Ling Chen, et al.. (2013). The Senescence-Associated Secretory Phenotype In Multiple Myeloma. Blood. 122(21). 5357–5357. 1 indexed citations

13.

Hurchla, Michelle A., Antonio García-Gómez, Enrique M. Ocio, et al.. (2012). The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects. Leukemia. 27(2). 430–440. 110 indexed citations

14.

Tomasson, Michael H.. (2009). Legal, ethical, and conceptual bottlenecks to the development of useful genomic tests.. PubMed. 18(2). 231–60, 8 p. preceding i. 6 indexed citations

15.

Tomasson, Michael H.. (2009). Cancer stem cells: A guide for skeptics. Journal of Cellular Biochemistry. 106(5). 745–749. 27 indexed citations

16.

Liu, Fulu, Maxwell M. Krem, William Eades, et al.. (2008). Csf3r mutations in mice confer a strong clonal HSC advantage via activation of Stat5. Journal of Clinical Investigation. 118(3). 946–55. 62 indexed citations

17.

Uy, Geoffrey L., Shachar Peles, Nicholas M. Fisher, et al.. (2007). Bortezomib Inhibits Osteoclast Activity in Patients with Multiple Myeloma. Clinical Lymphoma & Myeloma. 7(9). 587–589. 28 indexed citations

18.

Peles, Shachar, Nicholas M. Fisher, Feng Gao, et al.. (2006). A prospective study of the effects of once weekly bortezomib on markers of bone metabolism in patients with multiple myeloma (MM). Journal of Clinical Oncology. 24(18_suppl). 7548–7548. 7 indexed citations

19.

Devine, Steven M., R Brown, Vikram Mathews, et al.. (2005). Reduced risk of acute GVHD following mobilization of HLA-identical sibling donors with GM-CSF alone. Bone Marrow Transplantation. 36(6). 531–538. 18 indexed citations

20.

Schwaller, Juerg, Julie Frantsve‐Hawley, Jon C. Aster, et al.. (1998). Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes. The EMBO Journal. 17(18). 5321–5333. 213 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact